IASLC TTLC 2022

IASLC 2022 Targeted Therapies of Lung Cancer Meeting
23–26 February 2022 | Santa Monica, CA
The IASLC 2022 Targeted Therapies of Lung Cancer Meeting will take place February 23 – 26, 2022, and will feature novel research on emerging combination immunotherapy approaches and targets such as KRAS, G12C, and HER2. Relevant topics of effective therapeutic control of resistance to targeted therapies as well as the state of development of antibody-drug conjugates will be included in the program.   

IASLC TTLC 2022

IASLC 2022 Targeted Therapies of Lung Cancer Meeting
23–26 February 2022 | Santa Monica, CA
The IASLC 2022 Targeted Therapies of Lung Cancer Meeting will take place February 23 – 26, 2022, and will feature novel research on emerging combination immunotherapy approaches and targets such as KRAS, G12C, and HER2. Relevant topics of effective therapeutic control of resistance to targeted therapies as well as the state of development of antibody-drug conjugates will be included in the program.   
Moving immunotherapy and targeted therapies to the frontline setting 3:24
Moving immunotherapy and targeted therapies to the frontline setting
Jia Luo • 25 Feb 2022
Refining multimodal lung cancer therapies 1:05
Refining multimodal lung cancer therapies
Charles Simone • 28 Feb 2022
The role of co-stimulatory molecules in T cell therapies 1:08
The role of co-stimulatory molecules in T cell therapies
Prasad Adusumilli • 8 Mar 2022
Radiotherapy highlights at TTLC 2022 1:06
Radiotherapy highlights at TTLC 2022
Charles Simone • 28 Feb 2022
Optimizing CAR T-cell therapies for thoracic cancers 1:28
Optimizing CAR T-cell therapies for thoracic cancers
Prasad Adusumilli • 8 Mar 2022
Entrectinib in patients with solid tumors and brain metastases 1:31
Entrectinib in patients with solid tumors and brain metastases
Christian Rolfo • 10 Mar 2022
MRD testing platforms for lung cancer 2:48
MRD testing platforms for lung cancer
Christian Rolfo • 10 Mar 2022
Treating BRAF V600E-mutant NSCLC with dabrafenib and trametinib 2:56
Treating BRAF V600E-mutant NSCLC with dabrafenib and trametinib
Bruce Johnson • 9 Mar 2022
Current challenges in targeting solid tumors with CAR T-cells 2:36
Current challenges in targeting solid tumors with CAR T-cells
Prasad Adusumilli • 8 Mar 2022
Advances in screening techniques for lung cancer 2:38
Advances in screening techniques for lung cancer
Prasad Adusumilli • 8 Mar 2022
Novel treatment strategies for BRAF V600E-mutant NSCLC 1:26
Novel treatment strategies for BRAF V600E-mutant NSCLC
Bruce Johnson • 9 Mar 2022
LDS1 as a potential target in SCLC 3:46
LDS1 as a potential target in SCLC
Triparna Sen • 21 Feb 2022
Upcoming trends in the lung cancer treatment landscape 0:59
Upcoming trends in the lung cancer treatment landscape
Liza Villaruz • 18 Feb 2022
Updates in the SCLC treatment landscape 0:54
Updates in the SCLC treatment landscape
Triparna Sen • 21 Feb 2022
Evaluating the role of systemic therapies in SCLC 1:02
Evaluating the role of systemic therapies in SCLC
Triparna Sen • 21 Feb 2022
Immunotherapy as combination and neoadjuvant therapies in NSCLC 3:44
Immunotherapy as combination and neoadjuvant therapies in NSCLC
Jay Lee • 18 Feb 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals